Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: the eagle who wrote (714)	2/19/1998 9:34:00 PM
From: astro	Respond to of 1826

Man this is one spicy pepper!! <eom>

To: the eagle who wrote (714)	2/19/1998 10:59:00 PM
From: David Cathcart	Read Replies (2) \| Respond to of 1826

Eagle, <<give all of us some realistic view of what the prospects are for this drug based on data available in layman's terms.>> Richard Dean Bagnell is probably the best person to answer this so hopefully he will chime in tomorrow. In the lab experiments on human tumors in nude mice, MGI-114 was arguably the best drug ever developed in treating a broad range of solid tumors. However, mice and humans are different. The good news thus far from phase I is that humans can tolerate a reasonably high level of the drug. Phase II will reveal if the maximum tolerated dose level of MGI-114 is effective in shrinking tumors in humans. As RDB says, MGI-114 only has to work better than Taxol. Annual sales of Taxol are about 15 times the market cap of MOGN. At current MOGN prices, we get MGI-114 for free. Free is good. Let's go shrink some tumors. David